Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06700841 topical cream dose-ranging study in mild to moderate chronic plaque psoriasis
2018-003051-38Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing PF-06700841 topical cream dose groups with Vehicle control (2 arms). Primary endpoint: Change from baseline in Psoriasis Area and Severity Index. Started May 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2018-003051-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003051-38.